Diphenhydramine: From Antihistamine to Anticholinergic — A Comprehensive Pharmacology Review

Diphenhydramine is one of the most widely used over‑the‑counter agents in the United States, yet its pharmacologic breadth extends far beyond a simple antihistamine. Clinically, it is often the first line of treatment for acute allergic reactions, pre‑operative sedation, and insomnia, but it also plays a pivotal role in managing motion sickness, postoperative nausea, and even certain psychiatric conditions. In 2023, more than 15 million prescriptions for diphenhydramine were written for sleep disorders alone, underscoring its enduring relevance. Understanding its mechanisms, pharmacokinetics, and safety profile is essential for prescribers, pharmacists, and students preparing for licensing exams.

Introduction and Background

Diphenhydramine, first synthesized in 1943 by the German chemist Otto T. W. He discovered its antihistaminic properties while investigating anticholinergic compounds. It entered the United States market in 1947 under the trade name Benadryl and quickly became a household name for allergy relief. The drug belongs to the first‑generation antihistamine class, characterized by high lipophilicity and the ability to cross the blood‑brain barrier (BBB), which accounts for both its therapeutic benefits and central nervous system (CNS) side effects.

From a pharmacological standpoint, diphenhydramine is a potent antagonist at peripheral H1 histamine receptors and exhibits significant affinity for muscarinic acetylcholine receptors (mainly M1–M4). Its anticholinergic activity underlies many of its clinical applications, such as pre‑operative sedation and anti‑emetic effects. Epidemiologically, diphenhydramine is the most frequently reported non‑prescription drug implicated in emergency department visits for overdose, with approximately 2,500 cases annually in the United States.

In the context of drug development, diphenhydramine serves as a prototype for understanding the structure–activity relationships of phenothiazine derivatives and the balance between efficacy and adverse effect profiles in antihistamines.

Mechanism of Action

H1 Histamine Receptor Antagonism

At the molecular level, diphenhydramine competitively inhibits histamine binding to the H1 receptor, a Gq‑coupled protein that normally activates phospholipase C, increasing intracellular calcium and promoting smooth muscle contraction, vasodilation, and pruritus. By blocking this pathway, diphenhydramine reduces the classic allergic symptoms of erythema, edema, and itching. The drug’s high lipophilicity allows it to penetrate the BBB, where it also antagonizes central H1 receptors, contributing to its sedative properties.

Antimuscarinic (Anticholinergic) Activity

Diphenhydramine’s structure confers affinity for muscarinic acetylcholine receptors. It acts as a non‑selective antagonist at M1–M4 subtypes. In the CNS, M1 blockade reduces cortical arousal, while peripheral M3 blockade decreases secretions (salivary, bronchial, gastric) and smooth muscle tone. The anticholinergic effects are responsible for its antiemetic action (by inhibiting the chemoreceptor trigger zone), its ability to reduce postoperative nausea, and its side effect profile of dry mouth, blurred vision, and urinary retention.

Other Pharmacologic Interactions

Diphenhydramine also exhibits weak affinity for 5‑HT2A receptors and alpha‑1 adrenergic receptors, contributing to mild antihistaminic and vasodilatory effects. Its inhibition of the Na⁺/K⁺‑ATPase in cardiac myocytes at high concentrations can precipitate arrhythmias, a key consideration in overdose scenarios.

Clinical Pharmacology

Pharmacokinetic (PK) parameters of diphenhydramine are as follows:

Pharmacodynamic (PD) data show a dose–response relationship with a therapeutic window of 25–50 mg for antihistaminic effects and 50–100 mg for sedation. The drug’s onset of action is dose‑dependent, with higher doses producing more pronounced CNS depression.

Comparison of PK/PD parameters across related first‑generation antihistamines:

Therapeutic Applications

• Allergic Rhinitis and Urticaria: 25–50 mg PO q6–8 h as needed. Effective in both acute and chronic allergic symptoms.
• Insomnia: 25–50 mg PO at bedtime; not recommended for chronic use due to tolerance and daytime sedation.
• Pre‑operative Sedation: 25–50 mg PO 1–2 h before surgery; often combined with local anesthetics.
• Motion Sickness and Post‑operative Nausea: 25–50 mg PO q6–8 h; can be given orally or rectally.
• Anticholinergic for Parkinsonian Tremor (off-label): 25–50 mg PO q6–8 h; limited evidence but used in refractory cases.
• Viral Rhinovirus Symptom Relief (off-label): 25–50 mg PO q6–8 h; reduces nasal congestion and cough.

Special populations:

1. Pediatrics: Dosing 0.5–1 mg/kg PO q6–8 h; maximum 50 mg/day. Caution in infants <6 months due to risk of respiratory depression.
2. Geriatrics: Reduced clearance leads to prolonged half‑life; recommend 25 mg PO at bedtime only.
3. Renal Impairment: No dose adjustment needed for mild–moderate impairment; caution in severe renal disease due to accumulation of metabolites.
4. Hepatic Impairment: Dose reduction to 25 mg PO; monitor for prolonged sedation.
5. Pregnancy: Category C; limited data suggest potential teratogenicity; use only if benefits outweigh risks.
6. Breastfeeding: Low transfer to milk; safe at therapeutic doses, but monitor infant for sedation.

Adverse Effects and Safety

Common side effects (incidence in adults):

• Somnolence – 30–40 %
• Dry mouth – 20–25 %
• Blurred vision – 10–15 %
• Constipation – 5–10 %
• Urinary retention – <5 %

Serious adverse events include:

• Severe CNS depression – <1 %
• Cardiac arrhythmias (QT prolongation) – <0.1 %
• Anticholinergic toxicity (delirium, hyperthermia) – <0.05 %
• Severe hypersensitivity reactions – <0.01 %

Black box warnings: None currently, but the FDA recommends caution in patients with chronic obstructive pulmonary disease (COPD), glaucoma, urinary retention, and in the elderly due to increased risk of falls.

Drug interactions (major):

Monitoring parameters: In overdose, monitor ECG for QT prolongation, serum electrolytes, and mental status. In chronic use, assess for cognitive decline and falls risk in the elderly.

Contraindications: Severe hepatic or renal impairment, narrow angle glaucoma, prostatic hypertrophy, myasthenia gravis, and concomitant use with other CNS depressants.

Clinical Pearls for Practice

• “Sleep‑Aid” vs. “Allergy Med”: Diphenhydramine’s sedative effect is dose‑dependent; use the lowest effective dose for insomnia to minimize daytime drowsiness.
• Anticholinergic Toxicity: In elderly patients presenting with confusion, urinary retention, and dry mucosa, consider diphenhydramine overdose as a differential.
• Pregnancy Risk: Category C; if used, prefer second‑generation antihistamines with lower placental transfer.
• Drug Interaction Mnemonic: “A‑MAO‑SSR‑CYP2D6” – remember Alcohol, MAO inhibitors, SSRIs, and CYP2D6 inhibitors all enhance diphenhydramine’s effects.
• Overdose Management: Activated charcoal within 1 h, benzodiazepines for seizures, and cardiac monitoring; consider whole‑body cooling if hyperthermia develops.
• Pre‑operative Use: A single 25–50 mg dose 1–2 h before surgery reduces postoperative nausea and sedation without significant hemodynamic changes.
• Children <6 months: Avoid diphenhydramine due to high risk of respiratory depression; use antihistamine with lower CNS penetration.

Comparison Table

Exam‑Focused Review

Typical USMLE/NAPLEX question stems:

• “A 68‑year‑old woman presents with confusion, urinary retention, and dry mouth after taking an over‑the‑counter allergy medication. Which drug is most likely responsible?”
• “Which antihistamine is most likely to cause sedation due to its ability to cross the BBB?”
• “A patient with a history of glaucoma is prescribed an antihistamine for seasonal allergies. Which drug should be avoided?”

Key differentiators students often confuse:

• First‑generation vs. second‑generation antihistamines: first‑generation cross BBB → sedation; second‑generation are selective for peripheral H1 → minimal CNS effects.
• Diphenhydramine vs. hydroxyzine: both antimuscarinic, but hydroxyzine has stronger anxiolytic properties.
• Diphenhydramine vs. promethazine: both first‑generation, but promethazine has higher potency for antiemetic effect and stronger CNS depression.

Must‑know facts:

• Half‑life is prolonged in the elderly; use 25 mg at bedtime only.
• Contraindicated in narrow angle glaucoma.
• In overdose, monitor for QT prolongation and treat with activated charcoal and benzodiazepines.
• Drug interaction with CYP2D6 inhibitors can increase plasma concentration by up to 50 %.
• Use in pregnancy is Category C; consider second‑generation antihistamines if needed.

Key Takeaways

1. Diphenhydramine is a dual H1 antagonist and antimuscarinic with significant CNS penetration.
2. Its therapeutic window is narrow; dosing should start low, especially in the elderly.
3. It is FDA‑approved for allergic rhinitis, urticaria, insomnia, and motion sickness.
4. Common adverse effects are anticholinergic; serious toxicities include CNS depression and arrhythmias.
5. Key drug interactions involve alcohol, MAO inhibitors, SSRIs, and CYP2D6 inhibitors.
6. In overdose, monitor cardiac rhythm and treat with activated charcoal and benzodiazepines.
7. Use caution in patients with glaucoma, prostatic hypertrophy, and in the elderly.
8. For pre‑operative sedation, a single 25–50 mg dose 1–2 h before surgery is effective.
9. Pregnancy use is Category C; prefer safer alternatives.
10. Remember the mnemonic “A‑MAO‑SSR‑CYP2D6” to recall major interactions.

Always assess a patient’s overall anticholinergic burden before prescribing diphenhydramine, especially in the elderly, to prevent cognitive decline and falls.